Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation (CFF) is recognized as one of the earliest and best examples of venture philanthropy in medical research. It has provided more than $1 billion in research funding since 2005, actively supports dozens of new treatments in development, nine of them FDA-approved, and has industry partners including Vertex, Pfizer, PTC Therapeutics, and Genzyme.
Cystic Fibrosis Foundation Therapeutics
Established in 2000, Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) is the nonprofit drug discovery and development affiliate of CFF.
Drug Development Pipeline
CFF has built a dynamic pipeline of potential CF therapies in partnership with industry, and it keeps an up-to-date list of products in development on its Web site.
Industry Partnership Bears Fruit
In January 2012, the FDA approved Kalydeco, a drug developed by Vertex Pharmaceuticals, Inc. with significant scientific, clinical, and funding support from CFF. It is the first treatment targeting the underlying cause of CF in a subset of patients with a specific mutation.
Therapeutics Development Network
The Therapeutics Development Network is a nationwide network of nearly 80 CF clinical research centers. These centers specialize in conducting clinical trials to evaluate the safety and effectiveness of new CF therapies.
Coverage of the CF Foundation Model
12/27/12 - Forbes: The Most Important New Drug Of 2012
10/29/12 - Xconomy: The New Power Players in Drug R&D Are Wearing Bright T-Shirts
04/21/12 - The Economist: All together now
07/20/11 - Nature: With strings
05/02/11 - The New York Times: Helping New Drugs Out of Research's 'Valley of Death'
04/07/11 - Boston Business Journal: Vertex in $75M deal with CF foundation
01/17/11 - Institutional Investor: Disease Charities: The New Financiers of Drug Development
02/07/10 - Chronicle of Philanthropy: Charities Move Into Role Traditionally Held by Drug Companies [subscription required]
12/21/09 - The New York Times: Tool in Cystic Fibrosis Fight: A Registry
04/15/09 - Harvard Business School case: Bob Beall at the Cystic Fibrosis Foundation